Antidote for cocaine overdose developed

Washington -  Researchers have shed light on a treatment, which may reverse the effects of cocaine in case of emergency.

Scientists at The Scripps Research Institute have shown that an injectable solution can protect mice from an otherwise lethal overdose of cocaine.

The findings demonstrate the therapeutic potential of a human antibody against cocaine.

“This would be the first specific antidote for cocaine toxicity,” said Kim Janda, PhD, senior author of the report. A pioneer in the field of vaccines against drugs of abuse, Janda is the Ely R. Callaway, Jr. Chair in Chemistry, a professor in the Department of Immunology and Microbial Science, and director of The Worm Institute for Research and Medicine, all at Scripps Research.

“It’s a human antibody so it should be relatively safe, it has a superior affinity for cocaine, and we examined it in a cocaine overdose model that mirrors a real-life scenario,” he said.

Janda and his laboratory colleagues have been developing candidate vaccines against cocaine, heroin, nicotine, and even Rohypnol, the “date-rape” drug.

But most of these have been active vaccines—solutions of drug-mimicking molecules that provoke a long-term antibody response against a drug, greatly reducing its ability to reach the

brain.

These are potentially useful against addiction and relapse, but take weeks to stimulate an effective antibody response and thus are of limited value in drug overdose emergencies, which

require a fast-acting antidote. Cocaine is a leading cause of illegal-drug overdoses in developed countries; it can cause hyperthermia, irregular heartbeats, seizures and death.

One possibility for an antidote is a “passive” cocaine vaccine, a ready-made solution of antibodies much like those used to treat snakebite.

As Janda and his colleagues have shown in previous research, injected drug-specific antibodies can swiftly remove drug molecules from the bloodstream.

This immediately reduces a drug’s direct effects on the heart and nearby organs, but it also pulls the drug from the organ where it does the most damage—the brain. If the drug molecules

are small enough to cross the blood-brain barrier, the sudden lowering of their bloodstream concentration causes them to diffuse rapidly out of brain tissue.

Cocaine molecules are small enough to diffuse this way, and in 2005 Janda and his lab reported that injections of a mouse-derived anti-cocaine antibody, GNC92H2, could keep mice alive

despite cocaine doses that killed unprotected mice. Mouse antibodies are not ideal for use in humans, though; they are “foreign” enough that human immune systems eventually develop a

reaction against them.

In the new study, Janda and Jennifer B. Treweek, PhD, a research associate in Janda’s laboratory, used a genetically engineered mouse that can produce fully human antibodies against

cocaine molecules.

The best of these antibodies, GNCgzk, showed ten times the cocaine-binding affinity of GNC92H2, the molecule in the 2005 study.

In a preliminary test, the scientists showed an injection of GNCgzk antibodies 30 minutes before an injection of a lethal cocaine dose greatly reduced the signs of overdose—such as

awkward movements and seizures—and kept all treated mice alive.

By contrast, about half of untreated mice and 15 percent of GNC92H2-treated mice died.

In a test that better simulated a real-life emergency situation, mice were first given a cocaine overdose, and three minutes later were infused with GNCgzk. About half of untreated mice were

killed by such a dose. While GNC92H2 reduced that rate to about 28 percent, the new GNCgzk antibodies reduced the mortality rate further, to 20 percent.

More strikingly, a stripped-down version of GNCgzk—F(ab’)2-gzk, which contains only the antibody’s cocaine-binding segments—reduced the mortality to zero, as well as significantly

reducing overdose signs such as seizures. It also did so at a much smaller, clinically feasible dose than GNC92H2’s.

“There was a reversal of the signs of cocaine toxicity within seconds of the injection,” said Treweek.

Janda and Treweek are now trying to find ways to produce their F(ab’)2-gzk antidote economically and in large quantities.

“If we can do that, then there would be no reason not to push it into clinical trials,” Janda added.

He noted that such a treatment could be useful not only in reducing the immediate effects of an overdose, but also in preventing near-term relapses.

The study ahs been published in the journal Molecular Pharmaceutics.